Реперфузионное повреждение сердца. Роль микроваскулярной обструкции

Реперфузионное повреждение сердца. Роль микроваскулярной обструкции

Автор: Рябов В. В., Попов С. В., Вышлов Е. В., Сиротина М., Нарыжная Н. В., Мухомедзянов А. В., Деркачев И. А., Курбатов Б. К., Гомбожапова А. Е., Диль С. В., Самойлова Ю. О., Суфианова Г. З., Хлсткина М. С., Маслов Л. Н.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Рубрика: Обзоры и лекции

Статья в выпуске: 2 т.38, 2023 года.

Бесплатный доступ

Микроваскулярная обструкция (МВО) коронарных артерий способствует увеличению смертности и неблагоприятных сердечно-сосудистых событий у пациентов с острым инфарктом миокарда (ОИМ) и чрескожным коронарным вмешательством (ЧКВ). Были получены предварительные данные, свидетельствующие о том, что в патогенез МВО могут быть вовлечены тромбоциты, воспаление, Са2+-перегрузка, нейропептид Y и эндотелин-1. Многие вопросы, связанные с патогенезом МВО, остаются без ответа. Неизвестна роль повреждения эндотелиальных клеток в формировании МВО у пациентов с ОИМ и ЧКВ. Неясно, снижается ли продукция оксида азота (NO), или же снижается чувствительность гладкомышечных клеток коронарных артерий к NO у пациентов с МВО. Получены лишь косвенные данные об участии воспаления в развитии МВО. Роль активных форм кислорода в патогенезе МВО не изучена. Роль некроптоза и пироптоза в патогенезе МВО у больных с ОИМ и ЧКВ также не изучена. Значение тромбоксана А, вазопрессина, ангиотензина II и простациклина в формировании МВО до сих пор неизвестно. Не было получено убедительных данных об участии спазма коронарных артерий в развитии МВО. Не проводился корреляционный анализ уровней нейропептида Y, эндотелина-1 и размера МВО у больных с ОИМ и ЧКВ. Неясно, усугубляет ли эндогенный адреналин МВО или, напротив, предупреждает МВО.

Еще

Сердце, ишемия, реперфузия, микроваскулярная обструкция, no-reflow

Короткий адрес: https://sciup.org/149142828

IDR: 149142828   |   DOI: 10.29001/2073-8552-2023-39-2-14-22

Список литературы Реперфузионное повреждение сердца. Роль микроваскулярной обструкции

  • Majno G., Ames A., Chaing J., Wright R.L. No reflow after cerebral ischemia. Lancet. 1967;290(7515):569-570. https://doi.org/10.1016/S0140-6736(67)90552-1.
  • Kloner R.A., Ganote C.E., Jennings R.B. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 1974;54(6):1496-1508. https://doi.org/10.1172/JCI107898.
  • Schofer J., Montz R., Mathey D.G. Scintigraphic evidence of the “no reflow” phenomenon in human beings after coronary thrombolysis. J. Am. Coll. Cardiol. 1985;5(3):593-598. https://doi.org/10.1016/s0735-1097(85)80381-8.
  • Алексеева Я.В., Вышлов Е.В., Павлюкова Е.Н., Усов В.Ю., Марков В.А., Рябов В.В. Влияние разных фенотипов микрососудистого повреждения миокарда на сократительную функцию левого желудочка у пациентов с инфарктом миокарда с подъемом сегмента ST. Кардиология. 2021;61(5):23-31. https://doi.org/10.18087/cardio.2021.5.n1500.
  • McCartney P.J., Eteiba H., Maznyczka A.M., McEntegart M., Greenwood J.P. Muir D.F. et al.; T-TIME Group. Effect of low-dose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction: A randomized clinical trial. JAMA. 2019;321(1):56-68. https://doi.org/10.1001/jama.2018.19802.
  • McCartney P.J., Berry C. Redefining successful primary PCI. Eur. Heart J. Cardiovasc. Imaging. 2019;20(2):133-135. https://doi.org/10.1093/ehjci/jey159.
  • Ndrepepa G., Tiroch K., Fusaro M., Keta D., Seyfarth M., Byrne R.A. et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 2010;55(21):2383-2389. https://doi.org/10.1016/j.jacc.2009.12.054.
  • Rossington J.A., Sol E., Masoura K., Aznaouridis K., Chelliah R., Cunnington M. et al. No-reflow phenomenon and comparison to the normal-flow population postprimary percutaneous coronary intervention for ST elevation myocardial infarction: case-control study (NORM PPCI). Open Heart. 2020;7(2):e001215. https://doi.org/10.1136/openhrt-2019-001215.
  • Wu K.C., Zerhouni E.A., Judd R.M., Lugo-Olivieri C.H., Barouch L.A., Schulman S.P. et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97(8):765-772. https://doi.org/10.1161/01.cir.97.8.765.
  • Mayr A., Klug G., Schocke M., Trieb T., Mair J., Pedarnig K. et al. Late microvascular obstruction after acute myocardial infarction: relation with cardiac and inflammatory markers. Int. J. Cardiol. 2012;157(3):391-396. https://doi.org/10.1016/j.ijcard.2010.12.090.
  • Ober C.D., Ober M.C., Iancu A.C. Serial transthoracic coronary Doppler shows complete reversibility of microvascular obstruction pattern at one month after reperfused acute myocardial infarction. Med. Ultrason. 2017;19(1):45-50. https://doi.org/10.11152/mu-941.
  • Вышлов Е.В., Алексеева Я.В., Усов В.Ю., Мочула О.В., Рябов В.В. Синдром микрососудистого повреждения миокарда у пациентов с первичным инфарктом миокарда с подъемом сегмента ST: распространенность и связь с клиническими характеристиками. Сибирский журнал клинической и экспериментальной медицины. 2022;37(1):36-46. https://doi.org/10.29001/2073-8552-2022-37-1-36-46.
  • Romano M., Buffoli F., Lettieri C., Aroldi M., Tomasi L., Baccaglioni N. et al. No reflow in patients undergoing primary angioplasty for acute myocardial infarction at high risk: incidence and predictive factors. Minerva Cardioangiol. 2005;53(1):7-14.
  • Klug G., Mayr A., Schenk S., Esterhammer R., Schocke M., Nocker M. et al. Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 2012;14(1):46. https://doi.org/10.1186/1532-429X-14-46.
  • Kitabata H., Kubo T., Ishibashi K., Komukai K., Tanimoto T., Ino Y. et al. Prognostic value of microvascular resistance index immediately after primary percutaneous coronary intervention on left ventricular remodeling in patients with reperfused anterior acute ST-segment elevation myocardial infarction. JACC Cardiovasc. Interv. 2013;6(10):1046-1054. https://doi.org/10.1016/j.jcin.2013.05.014.
  • Porto I., Biasucci L.M., De Maria G.L., Leone A.M., Niccoli G., Burzotta F. et al. Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. Eur. Heart J. 2012;33(23):2928-2938. https://doi.org/10.1093/eurheartj/ehs065.
  • Jesel L., Morel O., Ohlmann P., Germain P., Faure A., Jahn C. et al. Role of pre-infarction angina and inflammatory status in the extent of microvascular obstruction detected by MRI in myocardial infarction patients treated by PCI. Int. J. Cardiol. 2007;121(2):139-147. https://doi.org/10.1016/j.ijcard.2006.10.022.
  • Zalewski J., Durak M., Lech P., Gajos G., Undas A., Nessler J. et al. Platelet activation and microvascular injury in patients with ST-segment elevation myocardial infarction. Kardiol. Pol. 2012;70(7):677-684.
  • Basili S., Tanzilli G., Raparelli V., Calvieri C., Pignatelli P., Carnevale R. et al. Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes. Circ. Cardiovasc. Interv. 2014;7(4):577-584. https://doi.org/10.1161/CIRCINTERVENTIONS.113.001197.
  • Takahashi T., Fukai T., Hata H., Kasuya H., Kuga T., Egashira K. et al. Effects of a new calcium antagonist, CD-832, on experimental coronary artery spasm in miniature pigs. Cardiovasc. Drugs Ther. 1993;7(2):265-271. https://doi.org/10.1007/BF00878517.
  • Ghaleh B., Dubois-Randé J.L., Hittinger L., Giudicelli J.F., Berdeaux A. Comparisons of the effects of nicorandil, pinacidil, nicardipine and nitroglycerin on coronary vessels in the conscious dog: role of the endothelium. Br. J. Pharmacol. 1995;114(2):496-502. https://doi.org/10.1111/j.1476-5381.1995.tb13254.x.
  • Abebe W., Makujina S.R., Mustafa S.J. Adenosine receptor-mediated relaxation of porcine coronary artery in presence and absence of endothelium. Am. J. Physiol. 1994;266(5):H2018-H2025. https://doi.org/10.1152/ajpheart.1994.266.5.H2018.
  • Ghaleh B., Béa M.L., Dubois-Randé J.L., Giudicelli J.F., Hittinger L., Berdeaux A. Endothelial modulation of beta-adrenergic dilation of large coronary arteries in conscious dogs. Circulation. 1995;92(9):2627-2635. https://doi.org/10.1161/01.cir.92.9.2627.
  • Lee S.R., Jung J.M., Jung L.Y., Lee J.H., Lee S.H., Rhee K.S. et al. Elevated coronary whole blood viscosity in acute coronary syndrome patients. Clin. Hemorheol. Microcirc. 2013;55(1):85-94. https://doi.org/10.3233/CH-131692.
  • Fracassi F., Vetrugno V., Mandurino-Mirizzi A., Cosentino N., Panicale S., Caprari P. et al. Effect of hemorheological parameters on myocardial injury after primary or elective percutaneous coronary intervention. Coron. Artery Dis. 2018;29(8):638-646. https://doi.org/10.1097/MCA.0000000000000661.
  • Tarantini G., Razzolini R., Cacciavillani L., Bilato C., Sarais C., Corbetti F. et al. Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty. Am. J. Cardiol. 2006;98(8):1033-1040. https://doi.org/10.1016/j.amjcard.2006.05.022.
  • Galiuto L., Garramone B., Scarà A., Rebuzzi A.G., Crea F., La Torre G. et al. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. J. Am. Coll. Cardiol. 2008;51(5):552-559. https://doi.org/10.1016/j.jacc.2007.09.051.
  • Zhang L., Mandry D., Chen B., Huttin O., Hossu G., Wang H. et al. Impact of microvascular obstruction on left ventricular local remodeling after reperfused myocardial infarction. J. Magn. Reson. Imaging. 2018;47(2):499-510. https://doi.org/10.1002/jmri.25780.
  • Dregoesc M.I., Iancu A.C., Ober C.D., Homorodean C., Bãlãnescu Ş., Bolboacã S. In ST-segment elevation myocardial infarction, the echocardiographic parameters of microvascular obstruction are not associated with left ventricular remodeling at five years of follow-up. Echocardiography. 2019;36(6):1103-1109. https://doi.org/10.1111/echo.14371.
  • Tsujioka H., Imanishi T., Ikejima H., Tanimoto T., Kuroi A., Kashiwagi M. et al. Post-reperfusion enhancement of CD14(+)CD16(-) monocytes and microvascular obstruction in ST-segment elevation acute myocardial infarction. Circ. J. 2010;74(6):1175-1182. https://doi.org/10.1253/circj.cj-09-1045.
  • Reindl M., Reinstadler S.J., Feistritzer H.J., Klug G., Tiller C., Mair J. et al. Relation of inflammatory markers with myocardial and microvascular injury in patients with reperfused ST-elevation myocardial infarction. Eur. Heart J. Acute Cardiovasc. Care. 2017;6(7):640-649. https://doi.org/10.1177/2048872616661691.
  • Holzknecht M., Tiller C., Reindl M., Lechner I., Troger F., Hosp M. et al. C-reactive protein velocity predicts microvascular pathology after acute ST-elevation myocardial infarction. Int. J. Cardiol. 2021;338:30-36. https://doi.org/10.1016/j.ijcard.2021.06.023.
  • Guo F., Dong M., Ren F., Zhang C., Li J., Tao Z. et al. Association between local interleukin-6 levels and slow flow/microvascular dysfunction. J. Thromb. Thrombolysis. 2014;37(4):475-482. https://doi.org/10.1007/s11239-013-0974-0.
  • Shetelig C., Limalanathan S., Hoffmann P., Seljeflot I., Gran J.M., Eritsland J. et al. Association of IL-8 with infarct size and clinical outcomes in patients with STEMI. J. Am. Coll. Cardiol. 2018;72(2):187-198. https://doi.org/10.1016/j.jacc.2018.04.053.
  • Abdelaziz H.K., Elkilany W., Khalid S., Sabet S., Saad M. Efficacy and safety of intracoronary verapamil versus sodium nitroprusside for the prevention of microvascular obstruction during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Coron Artery Dis. 2017;28(1):11-16. https://doi.org/10.1097/MCA.0000000000000423.
  • Hillegass W.B., Dean N.A., Liao L., Rhinehart R.G., Myers P.R. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J. Am. Coll. Cardiol. 2001;37(5):1335-1343. https://doi.org/10.1016/s0735-1097(01)01138-x.
  • Wang H.J., Lo P.H., Lin J.J., Lee H., Hung J.S. Treatment of slow/noreflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter. Cardiovasc. Interv. 2004;63(2):171-176. https://doi.org/10.1002/ccd.20149.
  • Niccoli G., Rigattieri S., De Vita M.R., Valgimigli M., Corvo P., Fabbiocchi F. et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc. Interv. 2013;6(6):580-589. https://doi.org/10.1016/j.jcin.2013.02.009.
  • Nazir S.A., McCann G.P., Greenwood J.P., Kunadian V., Khan J.N., Mahmoud I.Z. et al. Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial. Eur. Heart J. 2016;37(24):1910-1919. https://doi.org/10.1093/eurheartj/ehw136.
  • Taylor A.J., Bobik A., Richards M., Kaye D., Raines G., Gould P. et al. Myocardial endothelin-1 release and indices of inflammation during angioplasty for acute myocardial infarction and stable coronary artery disease. Am. Heart J. 2004;148(2):e10. https://doi.org/10.1016/j.ahj.2004.03.018.
  • Eitel I., Nowak M., Stehl C., Adams V., Fuernau G., Hildebrand L. et al. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. Am. Heart J. 2010;159(5):882-890. https://doi.org/10.1016/j.ahj.2010.02.019.
  • Tan C.M.J., Green P., Tapoulal N., Lewandowski A.J., Leeson P., Herring N. The role of neuropeptide Y in cardiovascular health and disease. Front. Physiol. 2018;9:1281. https://doi.org/10.3389/fphys.2018.01281.
  • Clarke J.G., Davies G.J., Kerwin R., Hackett D., Larkin S., Dawbarn D. et al. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet. 1987;1(8541):1057-1059. https://doi.org/10.1016/s0140-6736(87)90483-1.
  • Herring N., Tapoulal N., Kalla M., Ye X., Borysova L., Lee R. et al. Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction. Eur. Heart J. 2019;40(24):1920-1929. https://doi.org/10.1093/eurheartj/ehz115.
  • Aksu T., Guler T.E., Colak A., Baysal E., Durukan M., Sen T. et al. Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study. BMC Cardiovasc. Disord. 2015;15:10. https://doi.org/10.1186/s12872-015-0004-6.
  • Navarese E.P., Frediani L., Kandzari D.E., Caiazzo G., Cenname A.M., Cortese B. et al. Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI: The RESTORE observational study. Catheter Cardiovasc. Interv. 2021;97(4):602-611. https://doi.org/10.1002/ccd.29113.
  • Darwish A, Frere AF, Abdelsamie M, Awady WE, Gouda M. Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study. Ann. Saudi. Med. 2022;42(2):75-82. https://doi.org/10.5144/0256-4947.2022.75.
  • Zhao J., Yang Y., You S., Cui C., Gao R. Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Int. J. Cardiol. 2007;115(3):334-341. https://doi.org/10.1016/j.ijcard.2006.03.017.
  • Marzilli M., Orsini E., Marraccini P., Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101(18):2154-2159. https://doi.org/10.1161/01.cir.101.18.2154.
  • Ito H., Taniyama Y., Iwakura K., Nishikawa N., Masuyama T., Kuzuya T. et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J. Am. Coll. Cardiol. 1999;33(3):654-660. https://doi.org/10.1016/s0735-1097(98)00604-4.
  • Khan J.N., Greenwood J.P., Nazir S.A., Lai F.Y., Dalby M., Curzen N. et al. Infarct size following treatment with second-versus third-generation P2Y12 antagonists in patients with multivessel coronary disease at ST-segment elevation myocardial infarction in the CvLPRIT study. J. Am. Heart Assoc. 2016;5(6):e003403. https://doi.org/10.1161/JAHA.116.003403.
  • Ma Q., Ma Y., Wang X., Li S., Yu T., Duan W. et al. Intracoronary compared with intravenous bolus tirofiban on the microvascular obstruction in patients with STEMI undergoing PCI: a cardiac MR study. Int. J. Cardiovasc. Imaging. 2020;36(6):1121-1132. https://doi.org/10.1007/s10554-020-01800-0.
  • Aetesam-Ur-Rahman M., Brown A.J., Jaworski C., Giblett J.P., Zhao T.X., Braganza D.M. et al. Adenosine-induced coronary steal is observed in patients presenting with ST-segment-elevation myocardial infarction. J. Am. Heart Assoc. 2021;10(13):e019899. https://doi.org/10.1161/JAHA.120.019899.
  • Lim S.Y., Bae E.H., Jeong M.H., Kang D.G., Lee Y.S., Kim K.H. et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J. 2004;68(10):928-932. https://doi.org/10.1253/circj.68.928.
  • Knabb R.M., Ely S.W., Bacchus A.N., Rubio R., Berne R.M. Consistent parallel relationships among myocardial oxygen consumption, coronary blood flow, and pericardial infusate adenosine concentration with various interventions and beta-blockade in the dog. Circ. Res. 1983;53(1):33-41. https://doi.org/10.1161/01.res.53.1.33.
  • Buffington C.W., Feigl E.O. Adrenergic coronary vasoconstriction in the presence of coronary stenosis in the dog. Circ. Res. 1981;48(3):416-423. https://doi.org/10.1161/01.res.48.3.416.
  • Golino P., Maroko P.R., Carew T.E. The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation. 1987;75(1):292-298. https://doi.org/10.1161/01.cir.75.1.292.
  • Taniyama Y., Ito H., Iwakura K., Masuyama T., Hori M., Takiuchi S. et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 1997;30(5):1193-1199. https://doi.org/10.1016/s0735-1097(97)00277-5.
  • Huang R.I., Patel P., Walinsky P., Fischman D.L., Ogilby J.D., Awar M. et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc. Interv. 2006;68(5):671-676. https://doi.org/10.1002/ccd.20885.
  • Fischell T.A., Haller S., Pulukurthy S., Virk I.S. Nicardipine and adenosine “flush cocktail” to prevent no-reflow during rotational atherectomy. Cardiovasc. Revasc. Med. 2008;9(4):224-228. https://doi.org/10.1016/j.carrev.2008.03.002.
Еще
Статья обзорная
SciUp 2024 © 2024 ©